Alioth Achieves Over RMB 100 Million in Series A++ Financing, Accelerating Industrialization of Pharmaceutical Filtration Membrane Materials
Founded in 2021, Alioth is dedicated to providing high-quality separation and purification solutions for pharmaceutical process technologies that comply with domestic and international regulatory requirements. It aims to optimize the drug development and production processes of pharmaceutical companies and safeguard the supply chain security of domestic pharmaceutical enterprises. Meanwhile, the company has assembled a high-level talent team covering the entire chain of upstream filtration processes in biopharmaceuticals, from the research and development of underlying membrane materials, the research, development, and mass production of filters, GMP production and pharmaceutical validation regulations, to downstream process technology development and product business expansion. The middle and senior management teams possess decades of experience in research and development, management, technology, sales, and regulations at leading international membrane filtration companies.
Based on its "membrane technology" platform, Alioth has established core membrane material scientist teams with decades of industry experience in Shanghai, China, and Boston, USA. It is committed to building two research and development centers for "filtration membrane materials and filtration products," continuously strengthening its research and development capabilities for First/Best-In-Class membrane materials in the pharmaceutical field, and striving to become a filtration solution company with independent innovation, an international perspective, and international influence, equipped with underlying membrane materials.
As of now, Alioth's membrane material scientist team has developed high-performance filtration membrane materials with independent intellectual property rights by combining novel formulations, membrane material structures, and scaling-up processes. Leveraging a profound understanding of biopharmaceutical filtration processes, the company has systematically laid out research and development of a full range of membrane products, including "depth filter sheets, microfiltration membranes, ultrafiltration membranes, and virus removal membranes," focusing on product structure design, membrane material selection, injection molding material formulations, and product processes (welding, folding, etc.). It has also launched products such as "cartridge filters, capsule filters, disc filters, depth filters, filtration hardware systems, and laboratory filtration products."
Relying on its comprehensive research and development capabilities in filtration membrane materials and industrial layout, and with excellent product performance in parameters such as membrane material flux, loading capacity, retention efficiency, stability, and protein adsorption, Alioth's filtration product series have been successfully applied in the production processes of over 40 clinical Phase III/commercialized drugs. With over 100 application cases covering pharmaceutical fields such as antibodies, vaccines, recombinant proteins, blood products, CGT (Cell and Gene Therapy), and small molecules, the company comprehensively ensures the drug production safety of pharmaceutical enterprises.
Jia Qijun, the founder and CEO of Alioth, said, "We are grateful for the high recognition from Lapam Capital and Guohai Innovation Capital and the substantial financial support of over RMB 100 million, which will help the company achieve a systematic layout of the three dimensions of the pharmaceutical filtration industry: 'independent filtration membrane materials - filtration product research, development, and production - terminal commercial applications,' and accelerate the global commercial promotion of filtration products."
One of the focuses of this strategic financing round is to establish Alioth's membrane industrialization production line. On the one hand, it will enable the production of filter key consumables - filtration membranes, enhancing independent supply capabilities and strengthening core competitiveness. On the other hand, amidst the complex and changing geopolitical influences and the reconfiguration of the global pharmaceutical industry supply chain, as well as the acceleration of domestic pharmaceutical industry localization substitution/upgrading, this is a crucial move for Alioth to seize strategic development opportunities.
Alioth will remain true to its original aspiration, adhering to the development philosophy of "innovation-driven and quality-first." It will continuously enhance product innovation capabilities, strengthen business competitive moats, persist in taking "creating value for customers" as its core business, continuously refine high-quality filtration products to meet the development needs of the industrial ecosystem, integrate resources with an "ecological thinking" approach, and provide unique "Alioth" solutions for the global pharmaceutical industry.
The project leader from Lapam Capital stated, "With the rapid development of innovative drugs, the market size of upstream filtration membrane materials in pharmaceutical processes is vast. Meanwhile, driven by factors such as cost optimization and supply chain security, there is a strong willingness to replace imported upstream consumables. Alioth possesses research and development and independent innovation capabilities in underlying core membrane materials, addressing 'bottleneck' issues. It is a rare and valuable player in the industry. Currently, relying on its excellent product performance, Alioth has gained access from several leading domestic pharmaceutical companies. Leveraging the influence and demonstration effect of these leading customers, it can rapidly enhance brand awareness and market influence. We look forward to Alioth continuously launching better and more cost-effective products, safeguarding the supply chain security of pharmaceutical enterprises, helping customers optimize drug development and production processes, and improving drug production safety, ultimately achieving rapid catch-up and surpassing in terms of brand and market share in high-end biopharmaceutical applications."
The project leader from Guohai Innovation Capital said, "China's biopharmaceutical industry is booming, and the upstream bioprocess market in the industrial chain is experiencing rapid growth. As one of the core components of biopharmaceutical processes, the membrane filtration field has strong demand, and the trend of import substitution is clear, with vast growth potential. Through independent research and development, Alioth has broken the import monopoly and built a complete product line covering filtration membrane materials, filters, and hardware systems, providing biopharmaceutical companies with high-performance and cost-effective filtration solutions. It has also entered the supply chains of several leading domestic pharmaceutical companies, achieving key market breakthroughs. We are delighted to participate in this financing round of Alioth and look forward to the company continuously launching high-performance and cost-effective product series, growing into a benchmark enterprise leading the import substitution of upstream consumables, and contributing to the self-sufficiency of China's biopharmaceutical industrial chain."
The project team from Yishan Capital said, "We sincerely welcome the new shareholders, Lapam Capital and Guohai Innovation Capital, to join the Alioth family. Yishan Capital has deeply experienced the new shareholders' investment teams' profound understanding and unique insights into the biopharmaceutical filtration track industry. We jointly witness the rise and transformation of China's emerging biopharmaceutical filtration process player and look forward to Alioth 'remaining true to its original aspiration, accelerating the research and development and commercialization of filter products, meeting the filtration process needs of domestic pharmaceutical companies while deeply deploying global markets such as Europe and the United States, and accelerating the pace of global supply of membrane materials and filtration equipment.'"
Headquartered in Beijing, Lapam Capital is a leading biopharmaceutical venture capital institution in China. Currently, Lapam Capital manages five RMB funds and one USD fund, with a total scale exceeding RMB 10 billion. It is the only biopharmaceutical investment institution that has received investment support from China's top two RMB investors (LPs) - the National Social Security Fund and the National Small and Medium-sized Enterprise Development Fund.
Lapam Capital focuses on the fields of innovative drugs and innovative medical devices, with investment stages primarily in the early and early-to-mid stages. It has invested in a cumulative total of 200 enterprises, including over 160 innovative drug companies and more than 30 innovative medical device companies. Its portfolio includes numerous star projects such as Betta Pharmaceuticals (SZ.300558), RemeGen (SH.688331; HK.09995), Abmed (SH.688050), Ascendis Pharma (SH.688176), Kaiyin Technology (SH.688687), ImmuneOnco (HK.01541), Kangdini Pharmaceutical (NASDAQ: GYRE), Huahao Zhongtian (HK.02563), VBL Therapeutics (HK.09887), Binhui Biotech, Wuhe Boao, Bendao Gene, Microbiotech, Xinhanglu, etc.
The management team of Lapam Capital includes several partners with over 20 years of international/domestic biopharmaceutical industry research and development and management experience, providing comprehensive value-added services to invested enterprises.
Founded in January 2012, Guohai Innovation Capital is a securities private equity fund management subsidiary approved by the China Securities Regulatory Commission Guangxi Regulatory Bureau. It is also the platform for Guohai Securities (000750.SZ) to engage in private equity market investment fund management business, with a registered capital of RMB 2 billion. From 2019 to 2024, it has been consecutively rated as one of China's Top Ten Securities Private Equity Fund Management Institutions and among the Top 100 Best Private Equity Investment Institutions.
As a leading securities private equity fund management institution in China, Guohai Innovation Capital has continuously focused on the two main themes of "technological innovation" and "healthy living" over the years. It has initiated and managed multiple first-tier and first-tier-and-a-half equity investment funds, including listed company private placement and block trade equity investment funds, growth-stage equity investment funds, industry-themed investment funds, mezzanine merger and acquisition funds, and S-strategy funds. As of the end of June 2025, it has managed assets with a cumulative scale exceeding RMB 21.4 billion.
In recent years, Guohai Innovation Capital has actively shifted from a financial investment perspective to an industrial perspective, focusing on equity investment layout in strategic and high-tech industrial development fields such as medical and health, new energy, new materials, next-generation information technology, and aerospace. Among them, it has invested in 18 projects in the pharmaceutical and medical field, contributing to the development of China's pharmaceutical innovation industry while achieving substantial investment returns for investors. Guohai Innovation Capital adheres to the investment philosophy of rigorous pragmatism, value investment, and win-win cooperation, providing comprehensive capital market operation and value-added services to invested enterprises, assisting their growth, and creating long-term, stable, and high-quality investment returns for shareholders and investors.
